Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Jakafi
Descriptions
Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Myelofibrosis is a life-threatening bone marrow problem which is manifested by the following symptoms: enlarged spleen (splenomegaly), severe itching, fever, night sweats, weight loss, bone pain, or unusual tiredness or weakness. It is also used to treat polycythemia vera in patients who have been previously treated with hydroxyurea that did not work well.
Ruxolitinib is also used to treat acute graft-versus-host disease (aGVHD) in patients who have been treated with other medicines (eg, steroids) that did not work well. It is also used to treat chronic graft-versus-host disease (cGVHD) in patients who have been treated with 1 or 2 previous treatments that did not work well.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.